Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program December 19, 2023
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1 December 19, 2023
Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform December 19, 2023
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs) December 19, 2023
Ph 3 INTerpath-002 Study of V940 (mRNA-4157) – KEYTRUDA combination for Adjuvant Treatment of Patients with Certain Types of Resected NSCLC December 19, 2023
First Patient Dosed in Ph 2b Trial of Samuraciclib + Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer December 19, 2023
Enrollment of Ph 2/3 Trial of Fruquintinib + Sintilimab for Advanced RCC in China completed December 19, 2023
Confirmatory Ph 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer initiated December 19, 2023
FAILED TRIAL: RELATIVITY-123 Trial Evaluating the Fixed-Dose Combo of Opdivo + Relatlimab in Previously Treated MSS CRC Patients unlikely to meet primary endpoint, to be discontinued December 19, 2023
mRNA-4157 (V940) + KEYTRUDA Combination Demonstrated Continued Improvement in RFS and DMFS in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA At Three Years December 19, 2023
Complete Response In First Lymphoma Patient Treated With MT-601 Following CAR-T Relapse December 19, 2023
Topline Results from Ph 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM Announced December 19, 2023
FDA guides on the next Ph 2 study for advancement of Next Generation Capecitabine (“NGC-Cap”) for cancer patients December 19, 2023
Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma December 19, 2023
FDA Approves WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI December 19, 2023
FDA Approves Expanded Indication for KEYTRUDA Plus Padcev for 1L Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer December 19, 2023
